Forbes  1 hr ago  Comment 
In early trading on Thursday, shares of Eli Lilly & Co. (LLY) topped the list of the day's best performing components of the S&P 500 index, trading up 4.5%. Year to date, Eli Lilly & Co. registers a 24.7% gain.
TheStreet.com  2 hrs ago  Comment 
NEW YORK (TheStreet) -- Eli Lilly & Co. stock was upgraded by analysts at Bank of America/Merrill Lynch to "buy" from "neutral" and its price target was raised to $101 from $74. On Thursday, shares are rallying 2.87% to $84.71. Expectations...
FiercePharma  2 hrs ago  Comment 
Eli Lilly scored a victory in its patent battle for lung cancer blockbuster Alimta in Europe, as the Court of Appeal in London ruled against Actavis' plan to market copycat versions of the med.
newratings.com  5 hrs ago  Comment 
INDIANAPOLIS (dpa-AFX) - Eli Lilly and Company (LLY) announced that the Court of Appeal has ruled that the Alimta (pemetrexed disodium) vitamin regimen patent would be indirectly infringed by a generic competitor that had stated its intent to...
Benzinga  Jun 24  Comment 
In a report published Wednesday, SunTrust Robinson Humphrey analyst John T. Boris reiterated a Buy rating and $95 price target on Eli Lilly and Co (NYSE: LLY). The analyst estimates that the U.S. biologics psoriasis market would grow at a CAGR of...
MedPage Today  Jun 24  Comment 
(MedPage Today) -- Perry Wilson, MD, gives his take on Viagra, Cialis, and skin cancer
Benzinga  Jun 22  Comment 
Legendary investor and co-founder Home Depot Inc (NYSE: HD), Kenneth "Ken" Langone was on this week's edition of Wall Street Week where he discussed his current top-picks: Schlumberger Limited. (NYSE: SLB), Eli Lilly and Co (NYSE: LLY) and...
FierceBiotech  Jun 19  Comment 
Eli Lilly and Teva, racing with a pack of drugmakers with a new approach to treating migraines, said their respective injected therapies succeeded in midstage trials, setting the stage for pivotal studies.
newratings.com  Jun 19  Comment 
INDIANAPOLIS (dpa-AFX) - Eli Lilly and Co. (LLY) announced that The Lancet Oncology has published results of the Phase III REACH trial that evaluated Cyramza (ramucirumab) as a second-line treatment for people with hepatocellular carcinoma or HCC,...


Very nice site!

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki